KabaFusion, one of the nation’s biggest independent home infusion providers, is reportedly being acquired by Nautic Partners.
Reflecting the space’s interest and rising demand, the price tag on the home infusion deal is roughly $2.2 billion. That’s according to Axios, which cited three people familiar with the matter on Aug. 12.
The transaction would mark an exit for current owner Novo Holdings, which bought KabaFusion in 2022.
“KabaFusion’s model of improving patient outcomes and satisfaction at lower costs is exactly the type of health care business we need more of,” Jonathan Levy, a senior partner at Novo Holdings, said at the time.
Contextually, home infusion has drawn steady investor interest as care continues to shift to lower-cost sites. Option Care Health (Nasdaq: OPCH) – still the sector’s scale leader – has signaled an ongoing appetite for M&A even after its failed 2023 bid for Amedisys, which is currently being acquired by UnitedHealth Group (NYSE: UNH).
KabaFusion serves patients in 45 states through its network of home infusion pharmacies, alternative infusion sites and home health agencies. It has recently been an acquirer in its own right, buying Coram earlier this year.
“Our expansion will enable KabaFusion to serve a greater number of patients with superior care,” Dr. Sohail Masood, founder and CEO of KabaFusion, said in May. “Patient demand for home and ambulatory infusion services continues to increase, and we are thrilled to open new locations to meet the needs of our patients.”
On its end, Nautic is a veteran health care investor.
In 2024, Nautic Partners combined the assets of ExactCare Pharmacy with Tabula Rasa HealthCare in an acquisition that was finalized in 2023, creating the unified brand AnewHealth, which offers comprehensive medication management and pharmacy care services. VitalCaring Group and CarepathRx are other health care-focused investments.
If completed, the Nautic-KabaFusion deal would be one of the home infusion sector’s larger private-equity exits in recent years, reflecting investors’ confidence in specialty therapy growth even amid market headwinds.
Neither Nautic nor KabaFusion responded to requests for comment from HME Business.
